| Prev Close | 4.68 |
| Open | 4.66 |
| Day Low/High | 4.60 / 4.74 |
| 52 Wk Low/High | 1.70 / 5.11 |
| Volume | 1.18M |
BioDelivery Sciences International, Inc. (BDSI)
4.65
0.03
0.64
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 82.95B |
| Market Cap | 402.32M |
| Div & Yield | N.A. (N.A) |
Latest News
My Post-Earnings Assessment of 2 Biotech Stocks
Let's look at a couple of companies we have covered on these pages before.
3 Small Biotechs to Watch as Earnings Season Winds Down
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
3 Small Biotechs That Came Up Big on Thursday
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
3 Small Biotechs Turn on the Revenue Jets
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
4 Small-Caps on My Earnings Watch List
We are coming my favorite part of earnings season -- when these small-caps report.
3 Biotech Stocks on Readers' Minds
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
Trump's FDA: A Friendlier Biotech Sheriff
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
2 Recovering Biotech Names With Room to Run
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
4 Undervalued Biotech Stocks
Two are turnaround stories, and two are oversold.
2 Oversold Biopharmas With Big 2017 Upsides
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
3 Small Biotech Value Plays
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
Welcome to the Small-Cap Biotech Mailbag!
We answer recent reader questions about three of the biotech stocks we regularly cover.
BioDelivery Sciences Showing Strength
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...
My Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher this year.
Top 2017 Pick: Progenics Pharmaceuticals
This biopharma company's Relistor drug should send revenues sharply higher next year.
3 Small-Cap Biotech Names for 2017
In our last post we discussed large-cap biotech names that have been beaten up in 2016, are cheap and hopefully will see better days in 2017. Here are a few small-cap biotechs I would keep an eye on in 2017. The following is a quick rundown. Aratana...
Some 'January Effect' Stock Picks
Small-caps could also benefit from abating tax-loss selling.
Small Biotechs on My Shopping List
These small-caps are woefully undervalued after getting shellacked in October.
3 Stocks for Growth in 2017
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
Profiting on Small-Cap Biotech Earnings
Don't trade the headline numbers, but cash in on those traders that do.
M&A Could Ignite Next Leg Up for Biotech
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
Revisiting 3 Promising Small Biotechs
They are oversold and lately been on the move.
A Small Biotech Sells for Less Than Cash
And yet, Endocyte has a deep pipeline.
Watching Pernix as Futures Predict an Up Opening
The markets look based on the futures like they're heading for slight upwardly tilt in opening trading. Oil is touching $41 a barrel -- its best level of the year even as Russia's central bank is calling crude's recent rally "unsustainable." Of cour...
Biotech Rally Is Healing Small-Caps
This sector is finally bouncing from deeply oversold levels.
